Serotonin, (5 hydroxy-tryptamine), a naturally occurring compound, is pharmacologically active on intravenous injection in man. It consistently increases the pulse rate but has a variable pressor depressor, or biphasic effect on the arterial pressure. The mode of action of serotonin on these functions is not clear. Serotonin consistently and characteristically increases ventilation. However, it does not cause striking circulatory changes in the kidney although it usually produces moderate antidiuresis. The benzyl analog of serotonin (BAS) (1-benzyl-2-methyl-3-methoxy-tryptamine), both intravenously and orally, reduces or prevents the symptoms caused by serotonin. Intravenously, BAS in addition has demonstrable "antiserotonin" effects on the characteristic blood pressure and respiratory responses to serotonin. EROTONIN, chemically identified as 5-hydroxy-tryptamine, is a naturally occurring compound found mainly in the intestinal mucosa, the platelets, and the brain. Its concentration in the blood is low. The compound is rapidly inactivated by amine oxidase in the tissues and is excreted in the urine as 5-hydroxy-indoleacetic acid. Recently a clinical syndrome of malignant carcinoid of the small intestine with metastases to the liver has been described in which large amounts of serotonin are produced and released by the tumor.1'2 The physiologic role of serotonin in man is not clear but studies in animals suggest that the compound might participate in the regulation of hemostasis, arterial tone, renal function, and mental processes. 3' 4 To evaluate some of the possible functions of serotonin in man, its effects on blood pressure, respiration, and kidney function were studied after intravenous injection in subjects with and without arterial hypertension. Various types of blocking drugs (adrenergic, cholinergic, ganglionic, antihistaminic) and, in addition, one analog of serotonin, 1-benzyl-2-methyl-5- This investigation was supported in part by a grant from the National Heart Institute of the National Institutes of Health, U.S. Public Health Service, and in part by the Squibb Institute for Medical Research, New Brunswick, N. J. Presented in part at the Annual Scientific Sessions of the American Heart Association at Cincinnati, Ohio, October, 1956. 246 methoxy-tryptamine (BAS, Woolley*),5 were tested to determine their effectiveness as pharmacologic antagonists to serotonin. METHODS
Arterial blood pressure responses to serotonin creatinine sulfatet were studied in 20 normotensive and 35 hypertensive subjects without heart failure.
Most of the subjects were tested with single intravenous injections of serotonin given in increasing doses ranging from 0.25 to 2 mg. at intervals of at least 10 minutes. The effect of a given dose of serotonin on the blood pressure was also studied before and after the administration of phentolamine (Regitine), hexamethonium, atropine, pyrilamine (Neo-Antergan), diphenhydramine hydrochloride (Benadryl), reserpine, and BAS. The blood pressure was measured through an indwelling brachial artery needle with an electromanometer recording by direct-writing oscillograph. Respiratory responses to the same doses of intravenous serotonin were also studied in 30 of the subjects. Tidal lections, 3 or more, were designated the "recovery period," since the renal effects of serotonin were then usually no longer apparent.
In 7 subjects a single intravenous injection of BAS was given after the control period or after the administration of serotonin. In either case, the direct effect of BAS on renal function was followed for at least 3 15-minute periods ("BAS period") before its "blocking effects" on serotonin action were tested by repeating the standard test dose (1 mg.) (1, depressor; 2, depressor-pressor; 3, pressor) Depressor-Pressor Response. The depressorpressor or biphasic response, occurred more frequently when the dose of serotonin was increased to over 0.5 mg. It was characterized first by a brief fall in the blood pressure followed by an overshoot that lasted for 1 to 5 minutes. The changes in systolic and diastolic blood pressure ranged from 10 to 40 mm. Hg. Both the depressor and pressor components of this response were accompanied by increases in the pulse rate of 5 to 40 beats per minute.
Pressor Response. The pressor response occurred with increased frequency as the dose of serotonin was increased toward 2 mg. It was characterized by an increase in the blood pressure and pulse rate that lasted for 1 to 6 minutes. The increase in systolic and diastolic blood pressure ranged from 10 to 50 mm. Hg and the rise in pulse rate from 5 to 50 beats per minute. The response, like those previously described, occurred 15 to 45 seconds after the injection of serotonin and showed no diminution on repeated injections given at intervals of more than 10 minutes.
Serotonin produced mild to severe symptoms in three quarters of the 55 subjects tested. These symptoms lasted for 1 to 3 minutes and most commonly consisted of anxiety, dizziness, tingling of the extremities, substernal pressure, abdominal cramps, back pain, cough, and shortness of breath.
Effect of Various Drugs on the Brachial Arterial
Pressure Responses to Serotonin
Autonomic-Blocking Drugs (Regitine, hexamethonium, atropine). Regitine (phentolamine) given to 6 subjects in intravenous doses of 5 to 10 mg. failed to block completely the pressor action of 0.5 to 1 mg. of intravenous serotonin ( fig. 2 ). However, in 3 of the subjects Regitine reduced the pressor response to serotonin by 10 to 15 mm. Hg although it had no effect on the depressor effect.
Hexamethonium given intravenously to 5 subjects in hypotensive doses of 10 to 30 mg. did not alter the pressor or the depressor response to 0.5 to 1 mg. of intravenous serotonin ( fig. 3 ). The doses of hexamethonium administered produced ganglionic blockade as indicated by the appearance of postural hypotension and a "sympathectomy" type of brachial arterial pressure response to the Valsalva maneuver.7 Intravenous atropine in doses of 0.5 to 1 mg. likewise had no effect on these responses in 5 subjects. figure 6 . On the other hand, oral BAS given to 5 subjects in doses of 40 to 100 mg. a day for 1 month did not prevent the respiratory responses to intravenous serotonin.
Renal Effects of Intravenous Serotonin
The renal responses to intravenous serotonin are summarized in As with serotonin, BAS in 4 of 9 tests produced a reduction in urine flow which was irregularly accompanied by a reduction in the PAH and inulin clearances and electrolyte excretion ( fig. 7) . The ability of BAS in intravenous doses of 15 to 50 mg. to block the renal effects of serotonin was not striking. Only in subject B.R., who was studied on 2 separate occasions, were the findings definitely suggestive of a blocking action by BAS on the renal effects of serotonin. Oral BAS given to 3 subjects (H. L., M. S., and B. K.) in daily doses of 60 mg. for 1 month did not alter renal hemodynamic function at rest. It likewise did not appear to prevent the effects of intravenous serotonin on renal function.
DIscussIoN
Serotonin injected intravenously had a variable effect on the blood pressure but it consistently increased the pulse rate. In small doses it usually reduced the blood pressure whereas in larger doses it frequently caused an increase with or without an antecedent decrease. The manner in which serotonin affected the arterial pressure was not clear. Animal studies suggest that the blood pressure effects of serotonin are largely mediated through the autonomic nerv- Studies in animals indicate that reserpine reduces the body stores of serotonin.'0 Therefore, it was conceivable, since serotonin affects arterial pressure, that the hypotensive action of reserpine is mediated through its effect on serotonin metabolism. However, no conclusive evidence for this hypothesis was obtained from the present pharmacologic study, which showed that reserpine, administered orally or intravenously, had no significant effect on the blood pressure responses to intravenous serotonin except in 1 subject. Perhaps more sensitive biochemical studies will reveal a more definite causal relationship between the hypotensive and metabolic effects of reserpine.
The benzyl analog of serotonin, (BAS) synthesized by Drs. Woolley and Shaw,5 was capable of blocking the blood pressure and respiratory responses to serotonin and therefore was considered to be a definite anitiserotonin compound. However, in the doses used it did not consistently block the pharmacologic effects of serotonin. When administered orally, BAS had no demonstrable antiserotonin activity on the blood pressure or respiration but did partially or completely prevent the symptoms produced by intravenous serotonin.
Serotonin, in intravenous doses of 1 mg., had a definite but moderate antidiuretic effect that appeared to be due directly to serotonin itself. However, in those subjects with disturbing side reactions from serotonin, emotional factors might have operated to cause an antidiuresis. The reduction in urine flow caused by serotonin did not appear to be due to an effect of serotonin on the blood pressure, since it occurred with either an increase or a decrease in blood pressure. Evidence that serotonin also has a vasoconstrictor and salt-retaining action on the kidney was not conclusive in this study. Although slight reductions in renal plasma flow, glomerular filtration rate, and the excretion of sodium and potassium appeared to follow the administration of serotonin, they might have been due in part to decreases in urine flow.
Reductions in renal hemodynamic function and electrolyte excretion appeared to be real in some cases, however, since they occurred without similar changes in urine flow. Nevertheless, even in these subjects the was employed to examine the circulatory, pathologic, and biochemical alterations that followed mvocardial infarction. The media employed for the injections into the coronary circulation included gum acacia, human albumin, and (log plasma. Among the measurements obtained were blood gases; blood glucose pyruvate, lactate, and ketone bodies. Plasma enzyme measurements incluclecl transaminases, aldolase, isomerase, and inalic dlehy(lrogenase. Cardiac output an(l blood pressure (leterminations were recorded. Histopathologic (lata were studied at specific intervals from 20 minutes to 6 weeks following embolization.
The injection of spheres suspended in gum acacia resulted in decrease(l car(liac output, diminished coronoary flow and myOcardial oxygen consumption of more severe degree than occurred( with (log plasma or human albumin. The latter substances apparently led to coronary vasodilatation, possibly of reflex origin. The myocardlial extraction and utilization of lactate, pyruvate and ketones was immediately lowered following myocardial embolization. The extraction and consumption of glucose were less diminished due to the fact that anaerobic glvcolysis could still proceed under these conditions. These changes appeared to be rapidly reversible. The plasma activity of the enzymnes rose within 2 hours after embolization reaching a peak within 24 hours correlating with the height of coagulation necrosis of the infarcted myocardium. The pathologic changes consisted of a coagulative necrosis followed by polymorphonuclear infiltration reaching its peak in 2 or 3 days. The reparative phase marked by fibroblasts and mononuclear cells became well developed within 6 days. Cellularity diminished as collagen formation and fibrillary tissue was developec in the lesions.
A correlation of the data indicated that myocardial ischemia produced a period of decompensation of the affected heart muscle with a decrease in cardiac output and blood pressure. There were transient changes in substrate utilization and an increase in anaerobic activity of the heart muscle. The localized response appeared to be that of a coronary vasodilatation. Immediately thereafter, the muscle showed evidence of cellular necrosis the height of which coincided with the peak of plasma enzyme activity. This activity declined as reparative processes in heart muscle occurred. 
